FMP
Larimar Therapeutics, Inc.
LRMR
NASDAQ
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
4.01 USD
0.03 (0.748%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Carole S. Ben-Maimon M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.larimartx.comexchange
NASDAQ
Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
CIK
0001374690
ISIN
US5171251003
CUSIP
517125100
Address
Three Bala Plaza East
Phone
844 511 9056
Country
US
Employee
42
IPO Date
Jun 19, 2014
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
LRMR Financial Summary
CIK
0001374690
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
517125100
ISIN
US5171251003
Country
US
Price
4.01
Beta
0.71
Volume Avg.
859.94k
Market Cap
255.86M
Shares
-
52-Week
3.01-13.68
DCF
0.48
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-3.49
P/B
-
Website
https://www.larimartx.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest LRMR News
It looks like there's no news available.
